The immunohistochemical (IHC) detection was performed at the MSK Molecular Cytology Core Facility using
Discovery XT processor (Ventana Medical Systems). Paraffin-embedded tumor sections were deparaffinized with
EZPrep buffer (Ventana Medical Systems), antigen retrieval was performed with
CC1 buffer (Ventana Medical Systems) and sections were blocked for 30 minutes with Background Buster solution (Innovex).
Anti-CD3 (DAKO, cat# A0452, 1.2 ug/ml),
anti-CD4 (Ventana, cat#790-4423, 0.25ug/ml), CD8 (Ventana, cat#790-4460, 0.35ug/ml) and
anti-CD68 (DAKO, cat#M0814, 0.02ug/ml) antibodies were applied and sections were incubated for 5 h, followed by 60 minutes incubation with
biotinylated goat anti-rabbit IgG (Vector labs, cat#PK6101) for CD3, CD4 and CD8 antibodies or
biotinylated horse anti-mouse IgG (Vector Labs, cat# MKB-22258) for CD68 antibodies at 1:200 dilution. The detection was performed with
DAB detection kit (Ventana Medical Systems) according to manufacturer’s instruction. Slides were counterstained with hematoxylin and coverslipped with
Permount (Fisher Scientific). Images were captured from tumor sections using Nikon
ECLIPSE Ni-U microscope and NIS-Elements 4.0 imaging software, and counts of IHC-positive cells were averaged from two randomly selected fields (200X magnifications).
Xu H., Cheng M., Guo H., Chen Y., Huse M, & Cheung N.K. (2014). Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. Cancer immunology research, 3(3), 266-277.